Department of Gynecology and Obstetrics, School of Medicine, University of Udine, Udine, Italy (Dr Xodo).
Department of Obstetrics and Gynecology, St Antonius Hospital, Utrecht, The Netherlands (Dr Heus).
Am J Obstet Gynecol MFM. 2022 Sep;4(5):100639. doi: 10.1016/j.ajogmf.2022.100639. Epub 2022 Apr 13.
This study aimed to evaluate the effectiveness of intrapartum acute tocolysis for nonreassuring fetal heart rate tracing in decreasing the incidence of cesarean delivery. Secondary outcomes included modes of delivery other than cesarean delivery, successful acute tocolysis, time-to-delivery interval, and short-term perinatal outcomes.
Searches were performed in MEDLINE/PubMed, Embase, Scopus, the Cochrane Central Register of Controlled Trials and Reviews, ClinicalTrials.gov, and the International Clinical Trials Registry Platform from the inception of each database until February 2022.
Selection criteria included randomized controlled trials of laboring patients with singleton gestations randomized to receive intrapartum acute tocolysis for nonreassuring fetal heart rate tracing, as defined by the original trial.
All analyses were done using an intention-to-treat approach, evaluating women according to the treatment group to which they were randomly allocated in the original trials. A frequentist network-meta-analysis was performed.
Four randomized clinical trials were eligible, including 605 patients with nonreassuring fetal heart rate tracing and singleton gestations at gestational ages >32 weeks. The cesarean delivery rate was similar among patients managed with different types of acute tocolysis. Acute tocolysis, compared with emergency delivery, was associated with improved neonatal acid-base status (notably decreasing the prevalence of base deficit >12 mmol/L [beta-2 agonists odds ratio, 0.61; 95% confidence interval, 0.37-0.99] and the rate of neonatal intensive care unit admission [beta-2 agonists odds ratio, 0.42; 95% confidence interval, 0.22-0.78]) and with an increase in the time-to-delivery interval (beta-2 agonists mean difference, 17.62 minutes; 95% confidence interval, 15.66-19.58); there was no reduction of cesarean delivery rate, showing an increased rate with atosiban and beta-2 agonists.
The cesarean delivery rate was not reduced by acute tocolysis when used for nonreassuring fetal heart rate tracing during labor. Acute tocolysis is associated with improved short-term fetal outcomes and safely increases the time-to-delivery interval.
本研究旨在评估产时急性宫缩抑制对胎心监护图形不典型的有效性,以降低剖宫产率。次要结局包括除剖宫产以外的分娩方式、急性宫缩抑制成功、分娩时间间隔和短期围产儿结局。
从每个数据库建立开始到 2022 年 2 月,在 MEDLINE/PubMed、Embase、Scopus、Cochrane 对照试验中心注册库和评价、ClinicalTrials.gov 以及国际临床试验注册平台进行了检索。
纳入标准为对具有单胎妊娠的产妇进行产时急性宫缩抑制的随机对照试验,该试验将胎心监护图形不典型定义为原始试验。
所有分析均采用意向治疗方法,根据原始试验中随机分配到治疗组的产妇进行评估。采用频繁项集网络荟萃分析。
四项随机临床试验符合条件,共纳入 605 例胎心监护图形不典型且孕周>32 周的单胎妊娠产妇。不同类型急性宫缩抑制的剖宫产率相似。与紧急分娩相比,急性宫缩抑制与新生儿酸碱状态改善相关(尤其是降低基础缺陷>12mmol/L 的发生率[β-2 激动剂比值比,0.61;95%置信区间,0.37-0.99]和新生儿重症监护病房入院率[β-2 激动剂比值比,0.42;95%置信区间,0.22-0.78]),并增加了分娩时间间隔(β-2 激动剂平均差异,17.62 分钟;95%置信区间,15.66-19.58);阿托西班和β-2 激动剂的剖宫产率增加,并未降低剖宫产率。
在产时胎心监护图形不典型时使用急性宫缩抑制并未降低剖宫产率。急性宫缩抑制与短期胎儿结局改善相关,并且安全地增加了分娩时间间隔。